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Abstract
Background: HIV-infected individuals rely on antiretroviral therapy (ART) to control viral replication. Despite abundant
demonstrable benefits, the multiple limitations of ART point to the potential advantages of therapeutic vaccination
approaches that could provide sustained host control of viral replication after discontinuation of ART. We provide evidence
from a non-human primate model that a therapeutic vaccine applied to the tonsils can maintain low viral loads after
cessation of ART.
Methodology/Principal Findings: Animals received 40 weeks of ART initiated 9 weeks after rectal SIVmac239 infection.
During ART, animals were vaccinated (or not) with AT-2 inactivated SIVmac239 using CpG-C ISS-ODN (C274) or polyICLC as
adjuvants. PolyICLC/AT-2 SIV vaccinated animals maintained viral loads ,3610
3 copies/ml for up to 16 weeks post-ART,
whereas the C274/AT-2 SIV vaccinated and non-vaccinated animals’ viremia ranged between 1610
4–4610
5 copies/ml
(p,0.03). Neutralizing Ab activity in plasma was increased by polyICLC/AT-2 tonsillar vaccination under ART, compared to
controls (p,0.03). Subsequent vaccination of all animals with polyICLC/AT-2 SIV in the absence of ART did not alter viral
loads. Other immune parameters measured in blood and tissues were comparable between groups.
Conclusions/Significance: These results provide support for the potential benefit of mucosally delivered vaccines in
therapeutic immunization strategies for control of AIDS virus infection.
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Introduction
Human immunodeficiency virus (HIV-1) infection affects more
than 33 million people world-wide, including more than 300,000
children (WHO/UNAIDS). Left untreated, it leads to acquired
immune deficiency syndrome (AIDS) and death. More than 2
million people a year die of AIDS-related illness. Whilst a vaccine
for HIV remains elusive, major advances in therapies have been
made in the last decade.
Highly active anti-retroviral therapy (HAART), introduced in
1996, has so far been very effective in controlling viral replication
and preventing the progression of treated patients to AIDS [1].
HAART consists of combination antiretroviral drug therapy, using
agents that block different parts of the viral replication cycle.
However, despite its impressive demonstrable benefits [2,3]
HAART has major drawbacks. First and foremost, cost and
logistical issues have so far precluded delivery of HAART to the
majority of infected individuals worldwide who could benefit from
this therapy. Drug toxicity and emergence of drug resistant mutant
viruses also represent significant challenges [4]. It is also becoming
clear that even patients in whom viral replication is effectively
suppressed long term can develop serious sequelae [5]. Thus,
despite its many benefits, HAART does not represent a definitive
approach to the treatment of HIV infection, and harnessing host
responses to enhance control of viral replication represents an
obvious complementary approach.
Therapeutic vaccination offers the promise of enhancing host
antiviral immune responses by immunization under the cover of
antiretroviral drug suppression of viral replication, potentially
enabling durable control of viral replication even after subsequent
discontinuation of HAART. However, most studies of therapeutic
vaccination to date in HIV infected subjects have been
disappointing [6,7,8]. In this non-human primate (NHP) model
study, we employ a vaccine immunogen that has shown some
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12891promise in initial studies. We used TLR ligands as adjuvants,
immunizing via a mucosal route of administration to evaluate the
potential of a novel therapeutic vaccination regimen performed
during ART to enhance host control of viral replication following
discontinuation of antiretroviral drug therapy.
Aldrithiol 2 (AT-2) inactivated SIV has been shown to be
effective in inducing responses that can help control SIV infection
in macaques [9,10]. This type of chemical inactivation renders the
virus non-infectious by covalent modification of internal virion
proteins required for viral replication, whilst preserving the
structural and functional integrity of the viral envelope glycopro-
teins [11,12,13]. AT-2-treated viruses interact authentically with
DCs [14] and elicit both CD4
+ and CD8
+ T cell responses in vitro
[15]. Moreover, this type of inactivated virus has shown promise in
a therapeutic DC-based vaccines [10,16].
Vaccine immunogens are typically administered with adjuvants in
order to stimulate more optimal immune responses associated with
protective effects. Regularly used adjuvants range from broadly
immunostimulatory compounds, such as alum, to bacterial toxins,
such as cholera toxin B. Toll-like receptor (TLR) ligands have
recently been used as vaccine adjuvants due to their capacity to
mimic components of pathogens and stimulate immune responses.
CpG-C immunostimulatory oligonucleotides (CpG-C ISS-ODN)
bind to the intracellular TLR9 and have been shown to effectively
activate plasmacytoid DC (PDC) and B cell responses [17,18]. In
macaques, CpG-C ISS-ODNs have been shown to induce PDC-
derived IFNa and IL-12 production and boost SIV-specific T cell
responses in vitro [19], as well as B cell proliferation, survival and
activation [20]. Injection of CpG-C ISS-ODNs in macaque lymph
nodes also activated both DCs and B cells, demonstrating the ability
of CpG-C ISS-ODNs to work in vivo [21]. Whilst CpG-C ISS-ODNs
did not enhance the effect of AT-2 SIV as a preventative vaccine [9],
it is possiblethat their effect might be more pronounced in an already
primed, therapeutic vaccine setting. PolyIC is a TLR3 ligand that has
been recentlyshown to block DC-driven HIV replication, via a type-I
IFN-dependent pathway [22]. PolyIC has been used in past studies as
a vaccine adjuvant [23,24,25,26,27,28,29] and it was shown to be
effective in stimulating immune responses. It is thus an attractive
candidate for a SIV/HIV vaccine adjuvant.
Even though a therapeutic vaccine does not seek to prevent
establishment of infection after mucosal exposure in the manner a
preventative vaccine might, for therapeutic immunization mucosal
vaccination has distinct advantages over other routes, such as ease
of administration and lower cost. In this study, we tested tonsillar
therapeutic vaccination with AT-2 SIVmac239 adjuvanted with
CpG-C ISS-ODN vs clinical grade polyIC (Hiltonol or poly-
ICLC). We provide direct evidence of improved virus control
under ART after tonsillar immunization with AT-2 SIV and
polyICLC. This suggests that non-invasive mucosally applied
therapeutic vaccines augmented with polyICLC show promise in
controlling AIDS virus replication.
Materials and Methods
Animals and Treatment
Adult male Chinese Rhesus macaques (Macaca mulatta)w e r e
housed at the Tulane National Primate Research Center (Covington,
LA). All studies and the use of macaques were approved by the
Animal Care and Use Committee of the TNPRC (#A4499-01),
which has received continued full accreditation by the Association for
Accreditation of Laboratory Animal Care (AAALAC #000594). The
animals’ average age at the beginning of the study was 5 years and
their average weight was 10 kg. All animals tested negative for simian
type D retroviruses, simian T cell leukemia virus-1, and SIV prior to
use. Animals were housed and cared for in compliance with the
regulations detailed under the Animal Welfare Act, the Guide for the
Care and Use of Laboratory Animals [30,31]. Animals were
monitored continuously by veterinarians to ensure their welfare.
The TNPRC Division of Veterinary Medicine has established
procedures to minimize pain and distress through several means.
Animals were anesthetized prior and during all procedures (10 mg
ketamine-HCl/kg). The use of preemptive and post procedural
analgesia was required for procedures that would likely cause more
than momentary pain or distress in humans undergoing the same
procedure. All animals were inoculated rectally with 3610
3 TCID50
of SIVmac239. ART was given to all animals between 9 and 49
weeks post-infection (40 weeks in total) and consisted of PMPA
(20 mg/kg/day) and FTC (40 mg/kg/day), administered subcuta-
neously. The dosage was halved after 23 weeks of treatment due to
the low phosphorus levels in some animals, attributed to potential
ART toxicity. During therapy, test animals were vaccinated 4 times,
over 2 days each time (i.e. each of the 4 immunizations consisted of 1
vaccination per day for 2 consecutive days, which is the optimal way
of delivering polyICLC – A. Salazar, personal communication), with
C274/AT-2 SIVmac239 (1.5 mg of C274, 5 mgo fp 2 7
CA equivalent)
or polyICLC/AT-2 SIVmac239 (1 mg of polyICLC/HiltonolH,
5 mgo fp 2 7
CA equivalent) administered to the tonsillar tissue in a total
volume of 100 ml, applied over the palatine tonsils and the back of the
tongue, at 6 week intervals (starting on week 26 post infection).
Control animals did not receive any vaccination (adjuvant-only
controls groups were not included due to lack of extra animals). 5
weeks after the last immunization, ART was terminated for both
vaccines and unvaccinated controls. Table 1 lists all study animals
and their respective treatment groups. 20 weeks after ART ended all
animals were immunized with polyICLC/AT-2 SIVmac239, 4 times
over 2 days, at 6 week intervals (as above).
Immune responses were followed by collecting EDTA blood
(,10 ml/kg/month) and mucosal (oral and rectal) fluids through-
out the study. Mucosal fluids were collected as described
previously [9]. Blood, fluids and tissue samples were transported
for processing and analysis from the TNPRC to our laboratories at
the Population Council by overnight courier service and processed
as described previously [9]. Upon study termination or if an
animal became ill, animals were euthanized using methods
consistent with recommendations of the American Veterinary
Medical Association (AVMA) Panel on Euthanasia. Necropsy was
performed, when possible.
Reagents
CpG-C ISS-ODN C274 was provided by Dynavax Technologies
(Berkeley, CA). The sequence was: C274 59-TCGTCGAACGTTC-
GAGATGAT-39. PolyICLC (Hiltonol H)w a sp r o v i d e db yO n c o v i r
Inc. (Washington, DC). AT-2 SIV (AT-2 SIVmac239 lot numbers:
P4001, P4146, P3876, P3778, P3782) and the no virus microvesicle
(MV) controls (Lot numbers: P3826, P3971), prepared from the same
cell line in which the viruses were grown (SUPT1), were provided by
the Biological Products Core, AIDS and Cancer Virus Program, SAIC
Frederick, Inc. National Cancer Institute, Frederick (Frederick, MD).
AT-2 SIV was used at 300 ng of p27
CA/ml for all in vitro cultures. MVs
were normalized to SIV on total protein (300 ng of p27
CA/ml
equivalent). Concanavalin A (ConA; Sigma, St Louis, MO) was used at
1 mg/ml.
Cell isolation
Macaque peripheral blood mononuclear cells (PBMCs) were
isolated using Ficoll-Hypaque density gradient configuration (GE
Healthcare, Sweden). Cells were cultured in complete RPMI 1640
(Cellgro, Springfield, NJ) containing 2 mM L-glutamine (GIBCO
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hydroxyethylpiperazine-N’-2-ethanesulfonic acid) (GIBCO Life tech-
nologies), 50 mM 2-mercaptoethanol (Sigma), penicillin (100 U/ml)/
streptomycin (100 mg/ml) (GIBCO Life Technologies) and 1%
heparinized human plasma (Innovative Research, Southfield, MI).
Tissue biopsies were placed in RPMI (supplemented as above,
but with 10% heat inactivated fetal bovine serum (Mediatech,
Manassas, VA) instead of human plasma) containing 200 mg/ml
gentamycin (GIBCO) for 1 hour at 4uC. Lymph nodes were cut
in 2–4 mm pieces using a forceps and a scalpel and pushed
through a 70 mm nylon filter (BD Falcon) with a glass rod. The
suspension was spun at 340 g for 10 min. Cells were then
resuspended in RPMI (10% FBS) and counted. Jejunum and
ileum were washed by spinning at 244 g for 10 min and
resuspended in RPMI (10% FBS) containing 0.5 mg/ml
Collagenase II (Sigma, St Louis, MO) and 1 mg/ml DNAse I
(Roche, Indianapolis, IN) and 1 mg/ml hyaluronidase (Sigma) in
a T25 tissue-culture flask (BD Falcon). The tissue was broken up
using a forceps and a scalpel and incubated at 37uC for 30 min.
The suspension was then passed through a metal sieve using a
glass rod. Medium with enzymes, as above, was added to the
remaining tissue and incubated at 37uC for a further 30 min. The
suspension was passed through a metal sieve again and the
filtered suspension from both cases was then filtered using a
70 mm nylon filter. The remaining cell suspension was spun at
340 g for 10 min. Cells were then resuspended in RPMI (1%
human plasma) and counted.
Viral Load and SIV Ab detection
Plasma samples were collected from all animals at all time
points of the study, as described previously [9]. SIV RNA was
determined by quantitative RT-PCR [32] and SIV-specific Abs
were measured by ELISA [33].
Neutralizing Ab activity against SIVmac251 was measured in
monkey plasma samples, as described previously [9], with minor
adaptations. Briefly, heat-inactivated (56uC, 1 h) plasma was pre-
incubated with virus (50 TCID50)f o r1ha t3 7 uC before adding
3610
5 174xCEM cells per well (96 well flat bottomed plate).
Additional plasma was added on days 3 and 5 of culture. Plasma was
tested at 1:40, 1:100, 1:500, 1:2,500, and 1:12,500 final dilutions.
Cell-free supernatants were collected at day 7 and infection measured
by p27 ELISA. Pooled plasma from SIVmac239Dnef/wild type-
infected animals (healthy, long-term infected) was used as a positive
control. Pooled plasma from uninfected monkeys was used as a
negative control alongside a no plasma control.
SIV-specific IgA was measured in rectal and/or intestinal fluids
collected at the beginning of the study, at the last time point prior
to vaccination (week 26) and at necropsy by ELISA as previously
described [34], with minor modifications [9].
IFNc ELISPOT
Numbers of IFN-c spot-forming cells (SFCs) responding to AT-
2 SIVmac239 in blood were measured by ELISPOT [19]. ConA
was used at 1 mg/ml as a positive control. Medium and MV
Table 1. Animal treatment details.
Immunization Animal ID
ART
responsive IFNc SIV Ab responses CD4 counts
Plasma Rectal Duodenum Ileum Jejunum Pre
Wk 1
post
ART
Wk 26
post
ART
Final
(necropsy)
C274/AT-2 SIV GJ39 + + +++ + - 850 302 683 1013
GJ47 + - +++ - + 944 508 385 584
GJ48 + + +++ - - 368 842 388 239
GJ50 + + +++ - - 482 1083 168 283
GJ53 + + +++ + - 991 1357 1009 785
BG93 +
* + +++ + + 584 538 672 272
polyICLC/AT-2 SIV GJ55 + + +++ + + 1020 192 824 1092
GJ57 + + +++ + n/a 1250 368 708 2091
CC48 + + +++ - + 390 440 477 235
DV67 + + +++ - - 121 537 457 598
DD94 + + +++ - - 351 394 637 502
GJ97 +
* + +++ - - 499 744 117 147
Control DA47 + - +++ - - 796 510 788 637
CM96 + + +++ n/a n/a 912 583 479 651
1
CK25 + + +++ n/a n/a 579 290 458 458
1
CL68 + + +++ n/a n/a 597 627 350 361
1
EL02 - + +++ n/a n/a 608 285 n/a n/a
GJ65 - + +++ n/a n/a 751 686 n/a n/a
*indicates partial ART responsiveness (i.e. viremia .30 copies/ml; see Fig. 1). IFNc positivity defined as .50 SIV-specific spots (SFC) per 10
6 cells at .2 time-points. SIV
Ab measured in the plasma were IgG, whereas in tissue fluids IgA was measured. Rectal fluid IgA was measured at three time-points (baseline, post-infection/pre-ART
and post-ART) and all animals were positive at both post-infection time-points. Intestinal tissue fluid IgA was measured at necropsy. CD4 counts are shown for 4 time-
points. Necropsies were scheduled at weeks 65–70 post ART cessation, except control animals that died earlier (weeks 42, 51 post-ART). Animals showing a large drop in
CD4
+ T cells relative to pre-infection values are in bold.
1Early necropsy due to sickness.
doi:10.1371/journal.pone.0012891.t001
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responses to these controls have been subtracted to reveal the
specific stimulus-induced responses.
Flow cytometry
Multi-color flow cytometry was used to characterize leukocyte
subsets and polyfunctional T cells in macaque blood and tissues. T
cells were characterized using Pacific Blue-conjugated anti-CD3
and PerCP-Cy5.5-conjugated anti-CD4 (clones SP34-2 and L200,
BD Biosciences), APC-conjugated anti-CD28 (clone CD28.2, BD
Biosciences), PE-conjugated anti-CD95 (clone DX2, BD Bioscienc-
es), PE-Cy7-conjugated anti-CD25 (clone M-A251, BD Bioscienc-
es), PE-conjugated anti-PD-1 (clone J105, eBioscience), PE-Texas
Red conjugated anti-CD38 (clone HIT2, Invitrogen) and APC-
Cy7-conjugated anti-CD69 (clone FN50, BD Bioscie3nces).
Alexa488-conjugated anti-FoxP3 (clone PHC101, eBioscience)
was used to identify Tregs. Intracellular cytokine staining (ICS)
was performed as previously described [35]. Cells were stained with
anti-CD3 and -CD4 (as above) and FITC-conjugated anti-TNFa
(clone MAb11, Biolegend), Alexa700-conjugated anti-IL-2 (clone
MQ1-17H12, Biolegend), PE-Cy7-conjugated anti-IFNc (clone
B27, BD Biosciences) and Alexa647-conjugated anti-IL-17 (clone
eBio64CAP17, eBioscience).
Appropriate irrelevant specificity isotype Ig negative controls
were included in all experiments and typically gave MFIs of ,1
log. Samples were acquired on a LSR-II (BD) and analyzed using
FlowJo software (Tree Star, OR).
Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) for immune markers
RNA was extracted from cell pellets (10610
6 cells) using the
RNeasy Mini Kit (Qiagen, MD) according to the manufacturer’s
instructions. RNA was immediately quantified using a Nanodrop
spectrophotometer (Thermo Scientific, Wilmington, DE) and
converted into cDNA using the SuperScript VILO cDNA
Synthesis Kit (Invitrogen, Carlsbad, CA). Primers for IFNa,
IFNb, IFNc, TNFa, IL-2, IL-6, IL-10, IL-12, CCL4, CCL5,
CXCL10, FoxP3, IDO and TGFb were designed using Primer
Express (Applied Biosystems, Foster City, CA) and manufactured
by IDT (Coralville, IA). The PCR mixture was set-up as follows,
per reaction: 12 ml SYBR Green Master Mix (Applied Biosystems,
Warrington, UK), 100 nM forward primer, 100 nM reverse
primer, 50 ng cDNA and the reaction was made up to 25 ml with
distilled water. The program used was 95uC for 10 min, followed
by 40 cycles of 95uC for 15 sec and 60uC for 1 min. The reactions
were run on an ABI 7700 machine (Applied Biosystems, CA).
Statistical analyses
Data were analyzed for statistical significance using the
Wilcoxon Rank-Sum test in all cases apart from within-group
before-after comparisons for neutralizing Ab titers, where the one-
sided Wilcoxon Signed-Rank test was used. p values ,0.05 were
taken as statistically significant.
Results
Tonsillar polyICLC/AT-2 SIV vaccination maintains low
viremia
TLR ligands have been previously shown to be effective
inducers of the innate immune response and effective adjuvants.
We thus set out to examine two different TLR ligands, polyICLC
and CpG-C ISS-ODN C274, as adjuvants in therapeutic
vaccination with AT-2 inactivated SIVmac239 in SIVmac239
infected Rhesus macaques. Tonsillar vaccination was used as a
model of targeting oral mucosal-associated lymphoid tissue and
has been shown by us and other laboratories to be an effective port
of entry for immunogens [9,36,37,38].
18 SIV-naı ¨ve Chinese Rhesus macaques were inoculated
rectally with pathogenic SIVmac239. Infection was confirmed by
plasma SIV RNA PCR. Statistical analyses of early plasma
viremia (weeks 1–9) showed no differences between the groups,
including the setpoint viremia at 9 weeks when ART was initiated.
12 animals were vaccinated 4 times, at weeks 26, 32, 38 and 44
post-infection. 6 received the C274/AT-2 SIV vaccine, whereas
the other 6 received the polyICLC/AT-2 SIV vaccine. 6 control
animals were not vaccinated. 5 weeks after the final vaccination,
ART was withdrawn and the animals were followed up for a
further 4 months. Table 1 lists all animals and the treatment they
received.
All animals reached peak viremia at 2 weeks post-infection
(Fig. 1A). When ART was introduced, viremia was reduced to
below detection levels (30 copies/ml) within 5 weeks in almost all
animals. There were 4 notable exceptions: 2 monkeys responded to
ART partially (one in each vaccine group) and 2 in the control
group did not show any response to ART. Data from these animals
were excluded from some analyses, in which case it was indicated
that only the good ART responders (i.e. animals that achieved and
maintained viremia of ,30 copies/ml; referred to as ART
responders for simplicity) were included. Due to the small numbers
of animals we were unable to make significant comparisons between
the ART responders and partial or non responders.
Vaccination did not have a demonstrable effect on viral load
during the time animals were receiving ART as animals had
suppressed plasma viremia to below measurable levels prior to the
first immunization (Fig. 1A). Upon cessation of therapy, there was
a similar rebound (1–8610
4 RNA copies/ml at peak) in the viral
loads of all ART-responding animals in the control and C274/
AT-2 ISV vaccine groups. Interestingly plasma viremia in the
C274/AT-2 ISV vaccine group was on average higher and peaked
earlier than that observed for control animals (Fig. 1B), though
that difference was not statistically significant at any time-point. In
contrast, ART-responding polyICLC/AT-2 SIV vaccinated
animals had significantly smaller viral rebounds and all peaked
at ,3610
3 RNA copies/ml 3 weeks after stopping ART (Fig. 1B).
All animals were followed to 16 weeks post-ART. C274/AT-2 SIV
vaccinated animals and controls maintained high viremia, whereas
polyICLC/AT-2 vaccinees maintained lower viremia, with 2
animals having undetectable viral load (,30 copies/ml). Looking
at ART-responding animals, at weeks 2, 4, 8 and 16 post-ART
polyICLC/AT-2 SIV vaccinated animals had significantly lower
viremia than both C274/AT-2 SIV animals and controls (p,0.03
for both). At weeks 3 and 10 post-ART, polyICLC/AT-2 SIV
vaccinated animals had significantly lower viremia than C274/
AT-2 SIV vaccinees (p,0.02) and at week 13, polyICLC/AT-2
SIV animals had significantly lower viremia than controls
(p,0.03). The areas under the curves (AUC) of the viral loads
between 1 and 16 weeks post-ART (shown in Fig. 1B) were
calculated for each animal and the average for each group is
shown (Fig. 1C). Average AUC for the polyICLC/AT-2 SIV
animals was significantly lower than C274/AT-2 SIV (p,0.03)
and controls (p,0.02).
SIV-specific IFN-c responses were negligible during ART,
increasing post ART in all groups. Comparable levels of SIV-specific
T cell responses (normalized by subtracting any background in
response to MVs) were detected in the blood of the three treatment
groups, by IFN-c ELISPOT (Fig. 2A) and ICS for TNFa,I F N c,a n d
IL-2 after discontinuing ART (Fig. 2B). CD4 counts, as well as
Therapeutic Vaccine for SIV
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comparable across the 3 groups over time (Table 1).
Neutralizing Abs against SIVmac251 were detected in the blood
of all animals post-infection. No differences were observed
between animals assigned to the different treatment groups prior
to vaccination. Following vaccination with polyICLC/AT-2 SIV
under ART, neutralizing Ab titers increased $25-fold in all (6 of 6)
vaccinees (Fig. 3, p,0.02 relative to pre vaccination). Similar
increases were seen in 4 out of 6 C274/AT-2 SIV vaccinees, but
this was not significant (p,0.07 relative to pre vaccination). In
contrast, only 1 (DA47) of the 6 non-vaccinated control animals
had an increase in neutralizing Ab titer over time. Notably, this
was the animal that best controlled virus in that group upon
cessation of ART (Figure 1). Only the neutralizing Ab titer of the
polyICLC/AT-2 SIV vaccinated animals post vaccination was
significantly higher than the levels seen in the non-vaccinated
controls at the same time post infection (p,0.03).
The major histocompatibility complex (MHC) profile of each
animal was determined to ascertain if the animals with the reduced
viremia in the polyICLC-treated group had MHC alleles associated
Figure 1. Viral loads of polyICLC-treated animals are significantly lower, after cessation of ART. (A) Plasma SIV RNA copies/ml were
determined by PCR. Each symbol indicates an individual animal. The ART treatment period is indicated by the shaded grey box. Arrows indicate
immunization time-point. (B) Average (geometric means) viral loads (6SEM) are shown for the ART-responding animals (5 in the C274/AT-2 SIV group, 5
in the polyICLC/AT-2 SIV group and 4 in the control group). Asterisks indicate significant differences between: polyICLC vs both C274 and controls at
weeks 2, 4, 8 and 16, p,0.03; polyICLC vs C274 at weeks 3 and 10, p,0.02; polyICLC vs control at week 13, p,0.03. (C) Average Area Under the Curve
(AUC) is shown for the ART-responding animals in each group (6SEM). p,0.03 for polyICLC vs C274 and p,0.02 for polyICLC vs control.
doi:10.1371/journal.pone.0012891.g001
Therapeutic Vaccine for SIV
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12891with control of viral replication. The following molecules were
tested for: Mamu-A*01, Mamu-A*02, Mamu-A*08, Mamu-A*11,
Mamu-B*01, Mamu-B*03, Mamu-B*04, Mamu-B*08, Mamu-
B*17 and Mamu-DRB*w201. Only 3 animals (GJ48 in the
C274/AT-2 SIV group, GJ57 in the polyICLC/AT-2 SIV group
and DA47 in the control group) carried the B*03 and/or B*04
alleles, which have been associated with slow disease progression.
Late immunization with polyICLC/AT-2 SIV in the absence
of ART does not affect viremia
Having followed the animals for 4 months after cessation of ART
and established that the polyICLC/AT-2 SIV vacinees showed better
control of viral replication than the other groups, we evaluated the
effects of subsequent immunization with the polyICLC/AT-2 SIV
vaccine in the absence of ART in the animalsinitiallyvaccinated with
Figure 2. Similar SIV-specific responses in immunized and control animals. (A) Average SIV-specific (to AT-2 SIV) IFNc ELISPOT responses
are illustrated (6SEM). SIV specific responses were determined by subtracting the appropriate MV-induced background. (B) Percentage of cytokine
producing (IFNc, TNFa, IL-2 and combinations) CD3
+CD4
+ (upper panel) and CD3
+CD4
2 (lower panel) cells were measured in PBMC, by flow
cytometry at weeks 17–18 post-ART. Results shown in panels A and B (6SEM) are for 5 animals in the C274/AT-2 SIV group, 5 in the polyICLC/AT-2 SIV
group and 4 in the control group.
doi:10.1371/journal.pone.0012891.g002
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control animals. Animals in each original treatment group were
immunized with the polyICLC/AT-2 SIV vaccine, as described for
the initial vaccinations. The two control animals (EL02 and GJ65)
that had not responded to ART were excluded, having already been
euthanized. All animals received polyICLC/AT-2 SIV at 20, 26, 32
a n d3 8w e e k sp o s t - A R Ta n df o l l o w e du pf o r3m o n t h sa f t e rt h ef i n a l
immunization.
Plasmaviremiaappearedunaffectedbythe polyICLC/AT-2SIV
immunizations in the absence of concomitant ART (Fig. 4A). In the
original polyICLC/AT-2 SIV group, average viral loads remained
approximately 2610
3 RNA copies/ml for over 5 months after
cessation of ART vs 5610
4 and 2610
5 RNA copies/ml in the
original C274/AT-2 SIV and control groups respectively (Fig. 4B).
The average viremia of ART responders in the original polyICLC/
AT-2 SIV group was significantly lower than the original controls
(p,0.03) and than the original C274/AT-2 SIV group (p,0.04), at
all time-points up to week 34. Between weeks 34 and 46, statistical
significance was only achieved between the original polyICLC/AT-
2 SIV and the C274/AT-2 SIV group (p,0.04) and not with the
control group, due to the low number of animals remaining in the
latter group. These findings correspond to an AUC analysis
(Fig. 4C).SIVDNAlevelswerealso measuredinthelymphnodesat
necropsy with no significant differences observed between groups
(data not shown).
PolyICLC-induced immune responses and long term virus
control
More extensive examination of the adaptive immunity was
carried out in the hope of identifying the responses involved in the
improved long term control of virus replication in the original
polyICLC/AT-2 SIV vacinees. In all animals the frequency of
SIV-specific IFNc producing cells measured in blood was
unaltered by the polyICLC treatment in the absence of ART
(Fig. 5). Although the responses in the original polyICLC group
were often higher than those in the other groups, this was not
statistically significant at any time-point. Since the polyICLC/AT-
2 SIV vaccination under ART resulted in greater neutralizing Ab
responses (Fig. 3), we measured whether neutralizing Ab responses
were further boosted in all three groups after polyICLC/AT-2
SIV vaccination without ART. There were no significant changes
to the neutralizing Ab levels after poly ICLC/AT-2 SIV
vaccination without ART.
We also examined the immune responses by ICS (Tables 2, 3)
and RT-PCR (Fig. S2), as well as the distribution of CD25
+FoxP3
+
Tregs, CD95
2 naı ¨ve, CD95
+CD28
+ central memory and
CD95
+CD28
2 effector memory CD4
+ and CD4
2 T cell subsets
in the in blood, lymph nodes and gut tissues (ileum and jejunum),
at necropsy. CD38, CD69 and PD1 expression was investigated
(blood and tissues) as a measure of T cell activation (Fig. S1).
There were no detectable differences in the percentages of T cell
subsets and activated T cells between the two treatment groups.
TNFa, IFNc, IL-2 and IL-17 were measured by ICS. SIV-specific
single and double cytokine-producing cells were detected in most
animals (Tables 2, 3). No triple or quadruple cytokine-producing
‘‘polyfunctional’’ CD4
+ or CD8
+ T cells were detected at this time-
point. Similarly, there were no differences between the IFNa,
IFNb, IL-6, IL-12p35, FoxP3, IDO and TGFb RNA levels
detected in lymph nodes and jejunum of the two groups (Fig. S2A).
TNFa, IFNc, IL-2 and CCL5 appeared to be marginally elevated
in the polyICLC/AT-2 SIV group (Fig. S2B), although the
differences seen were not statistically significant. There was no
clear correlation between cytokine expression and plasma viral
load identified. Therefore, while polyICLC/AT-2 SIV therapeutic
vaccination under ART helped control viremia upon removal of
ART, the immune responses presumably underlying this enhanced
control remain unidentified.
Discussion
This study aimed to investigate the combination of AT-2
inactivated SIV with 2 TLR-binding adjuvants, C274 and
polyICLC, as a mucosal therapeutic vaccine for SIV-infected
macaques. We have previously shown AT-2 SIV to be partially
effective in preventing SIV infection in macaques [9]. C274 did
not enhance the immunogenicity of AT-2 SIV in the preventative
vaccine setting, but in infected, SIV-primed macaques it was
possible that it would be a more potent adjuvant when boosting
existing immunity. PolyIC was shown to effectively block HIV
replication in DCs in vitro [22], to upregulate CD80 expression on
blood mDCs in vivo following tonsillar application (E. Jasny and M.
Robbiani, unpublished data) and has been shown to be an effective
adjuvant [23,24,25,26,27,28,29]. Therefore, we decided to also
test the effectiveness of polyICLC (HiltonolH), as an adjuvant in a
separate group of animals.
ART consisted of a two-drug regimen that has been previously
shown to be partially effective in reducing plasma viremia [39]. In
this case, it was successful in reducing viral replication below the
limit of detection in all but four animals. The success in controlling
viremia is likely due to the Chinese origin of the macaques (vs.
Indian macaques used elsewhere). The lower levels of viremia at
Figure 3. PolyICLC/AT-2 SIV vaccination increases neutralizing Ab activity. Neutralizing Ab titers in the plasma were determined before and
after vaccination (vaccination on weeks 26, 32, 38, and 44 post infection). Levels were measured in samples taken 22 weeks after infection and 46
weeks post infection for all animals except CK25 (week 42) and EL02 and GJ65 (week 49) (asterisk). The titer (the last dilution tested at which infection
was blocked) is shown for each animal and the mean for each group is marked by the horizontal bar. The circled symbols denote the animals that
were ART partial or non-responders. Animal ID numbers are indicated for animals with outlier values relative to the rest of their respective groups.
doi:10.1371/journal.pone.0012891.g003
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responses to treatment, but are also a better match for the levels of
viremia typically seen in untreated HIV infected humans [40].
Statistical analyses of early plasma viremia did not reveal
significant differences between the groups prior to ART and
vaccination. The effectiveness of the two-drug (PMPA/FTC) ART
in reducing viral load suggests the usefulness of this model for
similar studies in the future.
After the test group animals were vaccinated four times during
ART, therapy was withdrawn. As expected from previous studies
in macaques [41] as well as humans [42] viremia in the non-
vaccinated control animals quickly rebounded to the levels seen
before treatment. Similar results were seen in the C274/AT-2 SIV
vaccinees. However, in the polyICLC/AT-2 vaccinated animals,
after a small spike of viral replication, plasma viremia appeared to
be successfully controlled for at least 4 months. In fact, in two out
Figure 4. Viral loads are not impacted by late immunization with polyICLC/AT-2 SIV without ART. (A) Plasma viral loads were
determined before, during and after treatment. Each symbol indicates an individual animal. Arrows indicate immunization time-point. (B) The average
viremia (geometric means) for each group (6SEM) is shown. Asterisks denote the statistically significantly lower virus levels in the polyICLC group
compared to the original C274 and/or control groups; p,0.04 for polyICLC vs C274 at weeks 23–46, p,0.03 for polyICLC vs control at weeks 20–34,
for good ART responders. (C) Average AUC is shown for each group (6SEM) for the time period shown in panel A. Asterisks mark the statistically
significant differences: polyICLC vs C274 at weeks 16–34, p,0.03; polyICLC vs control at weeks 16–34, p,0.03; polyICLC vs C274 at weeks 34–46,
p,0.05. Each group’s original treatment under ART is indicated in each panel.
doi:10.1371/journal.pone.0012891.g004
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vaccination are illustrated (6SEM). SIV specific responses were determined by subtracting the appropriate MV response.
doi:10.1371/journal.pone.0012891.g005
Table 2. Limited long-term cytokine/chemokine expression detected across groups (I).
CD4
+
TNFa IL-2 IFNc IL-17 TNFa + IL-2 TNFa + IFNc TNFa + IL-17 IL-2 + IFNc IL-2 + IL-17 IFNc + IL-17
GJ39 PBMC + - + -- + - ---
LN + -- + ++++ - +
GJ47 PBMC - - - - ---- - -
LN + -- - + - - ---
GJ48 PBMC + - ++ - ++- ++
LN
GJ50 PBMC + -- + - ++- + --
LN ++ + +---+ --
GJ53 PBMC + + + + +++- ++
LN ++ -- + - - ---
BG93 PBMC
LN - - + - ---- - -
GJ55 PBMC + + + + ++++ + +
LN
GJ57 PBMC + - + -- + - + --
LN + - + -- - + ---
CC48 PBMC
LN + - - - ---- - -
DV67 PBMC + - - - ---- - -
LN ++ - + ++++ + +
DD94 PBMC - - - - ---- - -
LN ++ + +- +++ - +
GJ97 PBMC - - - - ---- - -
LN + + + + ++++ + +
DA47 PBMC + + + + ++++ + +
LN ++ - + --+ ---
The expression of four cytokines was measured at the end of the study (week 46 post ART) by ICS of PBMC and lymph node (LN) cells. An average value of .0.01% was
taken as a positive. Plus-signs indicate positivity, minus-signs indicate negativity, whereas white cells indicate that a value was not determined for that condition. Single
and double cytokine combinations are shown. No triple or quadruple cytokine producing cells were detected. SIV-specific responses were measured by subtracting the
corresponding MV response. CD4
+ T cell cytokine production is shown.
doi:10.1371/journal.pone.0012891.t002
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limit of detection for the entire period (almost 1 year post-ART).
Thus, polyICLC/AT-2 SIV vaccination resulted in significantly
lower virus levels after ART. C274, was not effective as an
adjuvant in this case, as in the preventative vaccine setting [9]. A
recent study that used a CpG-B ISS-ODN in combination with
AT-2 SIV as a therapeutic vaccine, also failed to show efficacy in
controlling plasma viremia, despite augmented SIV-specific IFNc
responses [43]. These results suggest that therapeutic vaccination
of SIV-infected macaques undergoing ART with polyICLC/AT-2
SIV is effective in the post-therapy control of viral replication. As a
result, future studies will need to examine the effect of AT-2 SIV
vs. the polyICLC adjuvant alone (which was beyond the scope of
this study due to the limitation in animal numbers).
Since the polyICLC/AT-2 SIV vaccination showed promise
when administered under ART we were interested to assess how it
performed in the absence of ART. Unfortunately, polyICLC/AT-
2 SIV vaccination did not reduce plasma virus levels in any of the
groups in the absence of ART. However, there were no adverse
affects of the vaccination either. SIV-infected Rhesus macaques
develop symptoms of simian AIDS relatively rapidly [44]. The fact
that these animals remained healthy for up to one year after ART
was ended, suggests that the polyICLC/AT-2 SIV vaccinations
may have contributed to some degree of viral control in this setting
too. However, we were unable to include animals that did not
receive the additional polyICLC/AT-2 SIV treatment to know if
this had any impact on controlling progression.
We attempted to determine the correlates of immune control of
viral replication after the effective vaccination under ART as well
as after subsequent vaccination without ART, measuring a variety
of adaptive and innate responses in blood and tissues, but most
responses were comparable between groups at the time-points
measured. However, we were able to detect significantly higher
neutralizing Ab activity in polyICLC/AT-2 SIV vaccinees, after
the end of ART, which may account for some of the protective
effect of the vaccine. It is well established that high neutralizing Ab
activity is inversely correlated with plasma viremia [45]. Although
multiple cytokine producing ‘‘polyfunctional’’ cells have been
shown to play a key role in anti-SIV immunity [46] we did not
detect them in the polyICLC/AT-2 SIV vaccinated animals.
Additional studies are needed to clarify how the polyICLC/AT-2
SIV-induced virus control is being mediated (e.g., innate and/or
Table 3. Limited long-term cytokine/chemokine expression detected across groups (II).
CD4
2
TNFa IL-2 IFNc IL-17 TNFa + IL-2 TNFa + IFNc TNFa + IL-17 IL-2 + IFNc IL-2 + IL-17 IFNc + IL-17
GJ39 PBMC + - - - ---- - -
LN
GJ47 PBMC ++ -- - + - ---
LN
GJ48 PBMC
LN
GJ50 PBMC + - - - ---- - -
LN - - - + --+ - + -
GJ53 PBMC ++ - ++ -- + -
LN + + + + ++++ + +
BG93 PBMC - - + - ---- - -
LN ++ + +- ++- ++
GJ55 PBMC ++ + - ++++ - +
LN
GJ57 PBMC - - - - ---- - -
L N - - - - ---- - -
CC48 PBMC
LN + -- + --+ ---
DV67 PBMC ++ - ++ - + - + -
LN ++ -- +++- ++
DD94 PBMC + - - - ---- - -
LN ++ -- ++++ + +
GJ97 PBMC - - - - - +++ - +
LN - - - - ++- + - +
DA47 PBMC + + + + ++++ + +
LN + - - - ---- - -
The expression of four cytokines was measured at the end of the study (week 46 post ART) by ICS of PBMC and lymph node (LN) cells. An average value of .0.01% was
taken as a positive. Plus-signs indicate positivity, minus-signs indicate negativity, whereas white cells indicate that a value was not determined for that condition. Single
and double cytokine combinations are shown. No triple or quadruple cytokine producing cells were detected. SIV-specific responses were measured by subtracting the
corresponding MV response. CD4
2 T cell cytokine production is shown.
doi:10.1371/journal.pone.0012891.t003
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earlier time points during vaccination).
The role of Tregs in HIV infection is uncertain. They have been
shown to suppress HIV-specific T cell responses [47] but on the
other hand their numbers decline as disease progresses [48]. A
recent study has shown that CD4
+ Tregs can suppress CD8
+ T cell
responses after therapeutic vaccination [49]. CD8
+ Treg expan-
sion has been observed concurrently with reduced viral control
[50]. In our study, small numbers of CD4
+ Tregs were identified in
the gut of animals, but without significant differences between the
test groups. CD69 and CD38 expression was high and similar
between groups, consistent with immune activation. Programmed
death 1 (PD-1) is a T cell inhibitory receptor [51,52] that has been
associated with T cell exhaustion and failure to contain viral
infections, including HIV [53] and SIV [54]. Blockade of PD-1
has been associated with enhanced CD8
+ T cell response [55,56].
A recent study, however, suggested that increased PD-1 expression
on SIV-specific CD8
+ T cells should be viewed as a sensitive
indicator of low-level ongoing viral replication [57]. PD-1
expression was higher in CD4
+ T cells from the polyICLC/AT-
2 SIV group (although this was not significantly different to the
C274/AT-2 SIV group), both in the blood and in lymph nodes.
Given that we observed the lowest viral loads in this group and the
fact that cytokine production was measured in these cells, it would
be unlikely that this result represents dysfunctional T cells. It is
important to note that these analyses were only made at the end of
the study and more extensive monitoring at earlier time points
might reveal insight into the polyICLC/AT-2 SIV-mediated
control.
Another level of immune control might be dictated by the MHC
allele of individual monkeys. Certain macaque MHC alleles, like
Mamu-A*01 [58], B*08 [59] and B*17 [60], lead to better control
of SIV infection and disease progression. Others, such as Mamu-
DQB1*0601 [61], are associated with rapid disease progression.
Genotyping identified Mamu-B*03 and B*04, associated with slow
disease progression [62,63], in 3 macaques, one from each group.
This suggests that they do not play an important role in this
setting. It should be mentioned however, that previous studies on
protective alleles were performed on Indian rhesus macaques and
such alleles specific to Chinese macaques are yet to be defined.
Previous studies demonstrated beneficial therapeutic vaccina-
tion for SIV infection, administered intramuscularly [64,65,66].
Some have also demonstrated vaccine-induced immune responses,
but no control of post-ART viremia [43,67]. Herein we provide
the first evidence for the effectiveness of a mucosal therapeutic
vaccine for SIV with polyICLC as the adjuvant. Moreover, we
documented better control of viremia for a longer period of time
post-ART compared to previous studies. This strategy was
effective in boosting the animals’ immune system to control
plasma viremia to remarkably low levels – in some cases below the
limit of detection - for up to one year after the cessation of ART.
These findings set the stage for future work to develop polyICLC-
mediated augmentation of mucosally applied therapeutic vaccine
approaches to help control HIV.
Supporting Information
Figure S1 No correlation of T cell parameters with virus control
(A) T cell subsets and activation markers (in the CD3+CD4+ and
CD3+CD42 gates) were measured in PBMC, lymph nodes (LN),
jejunum and ileum of all available animals at the time of necropsy
(n=6 in C274/AT-2 SIV group, n=6 in polyICLC/AT-2 SIV
group). Tregs were defined as CD25+FoxP3+; naı ¨ve T cells as
CD952; central memory T cells (TCM) as CD95+CD28+ and
effector memory T cells (TEM) as CD95+CD282. Average
percentages for each group are shown (6SEM). (B) PD-1 surface
expression (CD4+PD1+ and CD42PD1+) was measured in
PBMC and LN of all animals at the end of the study, by flow
cytometry. Average percentages of PD-1 expressing cells per
vaccination group are shown (6SEM).
Found at: doi:10.1371/journal.pone.0012891.s001 (1.45 MB TIF)
Figure S2 Similar cytokine, chemokine and Treg marker
expression in tissues, between groups. RNA was extracted from
tissue cell pellets (106106 cells/pellet). RT-PCR was performed
for a range of cytokines and chemokines, as well as Treg markers.
(A) Jejunum and LN cell RNA expression of cytokines and Treg
markers. (B) Jejunum cell RNA expression of cytokines and
chemokines. mRNA levels are shown in arbitrary units (AU) which
were calculated by subtracting the threshold cycle (CT) number of
the gene of interest from 100, then normalizing by dividing with
(100-CT) of housekeeping gene b-actin, then multiplying by 100.
Means (6SEM) of 6 C274/AT-2 SIV and 4 polyICLC/AT-2 SIV
animals are shown for LN and 6 C274/AT-2 SIV and 3
polyICLC/AT-2 SIV animals for jejunum.
Found at: doi:10.1371/journal.pone.0012891.s002 (2.46 MB TIF)
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